|
KMID : 0620920230550102097
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 10 p.2097 ~ p.2104
|
|
|
Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases
|
|
Jeong Ye-Lin
Oh Ah-Reum
Jung Young-Hoon
Gi Hyun-Joon
Park Sung-Jun
Kim Kyeong-Jin
|
|
|
Abstract
|
|
|
|
Posttranslational modification of proteins via ubiquitination determines their activation, translocation, dysregulation, or degradation. This process targets a large number of cellular proteins, affecting all biological pathways involved in the cell cycle, development, growth, and differentiation. Thus, aberrant regulation of ubiquitination is likely associated with several diseases, including various types of metabolic diseases. Among the ubiquitin enzymes, E3 ubiquitin ligases are regarded as the most influential ubiquitin enzymes due to their ability to selectively bind and recruit target substrates for ubiquitination. Continued research on the regulatory mechanisms of E3 ligases and their adaptors in metabolic diseases will further stimulate the discovery of new targets and accelerate the development of therapeutic options for metabolic diseases. In this review, based on recent discoveries, we summarize new insights into the roles of E3 ubiquitin ligases and their adaptors in the pathogenesis of metabolic diseases by highlighting recent evidence obtained in both human and animal model studies.
|
|
|
KEYWORD
|
|
|
Mechanisms of disease, Metabolic disorders
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|